Latest Headlines

Latest Headlines

Almirall buys ready-made dermatology R&D operation in €365M deal

Almirall has splashed out €365 million ($386 million) on Poli Group. The takeover gives Almirall the dermatology R&D pipeline and infrastructure it has craved since it flogged its respiratory business to AstraZeneca for $2.1 billion last year.

JAMA: Valeant's 18-fold price hikes top widespread increases in dermatology prices

A new study shows that prices for 19 brand-name dermatology meds, including two from Valeant Pharmaceuticals, have increased almost fivefold, on average, over the past 6 years.

Aclaris limps out to a $55M IPO as biotech falters on Wall Street

Dermatology drug developer Aclaris Therapeutics priced its IPO well below its expected range, raising $55 million as a prolonged bear turn has dampened Wall Street's appetite for biotech debuts.

Oculus receives FDA clearance for novel, spray-based wound care formulation

Oculus Innovative Sciences announced that it has received FDA 510(k) clearance for its Alevicyn SG Antipruritic Spray Gel to treat dermatologic conditions like burning and itching skin, as well as skin irritation, lacerations, abrasions and minor burns.

Valeant CEO touts R&D output with new dermatology approval

Less than two weeks after losing longtime acquisition target Allergan--which happily sold itself to Actavis to dodge Valeant's hostile bid and the R&D cuts it feared would come along with it--the Canadian pharma is talking up the productivity of its own labs.

Revance tanks on fresh delays for its next-gen Botox

Revance Therapeutics' top prospect, a topical successor to Botox, has fallen off schedule, putting off the company's Phase III plans until next year and sending its shares southward.

Dermira pockets $51M to bankroll skin treatments

Well-funded biotech Dermira has landed a $51 million C round to support its late-stage dermatology pipeline, rallying some high-profile investors as it dials up R&D spending and builds out its management team.

Valeant offloads aesthetic treatments to Nestlé's derm unit in $1.4B deal

Valeant CEO J. Michael Pearson is an aggressive buyer, especially when it comes to the fast-growing skincare field. But Pearson was also a seller Wednesday, shipping off rights to a handful of cosmetic products to Nestlé as the Swiss food group looks to expand into the dermatology space.

Meet RestorGenex, a biotech mosaic from Celgene founder Barer

Nearly three years removed from his Celgene retirement, Sol Barer is working to get another biotech off the ground, piecing together four drugmakers into a whole called RestorGenex and setting out to make a difference in dermatology, ocular diseases and women's health.

Nestlé plans to use its global marketing juju to rev up Galderma

Nestlé has caught the dermatology fever sweeping through Big Pharma, as companies key in on the specialty sector's growth potential. But success for Galderma, its recent skincare pickup, will depend on the global food giant's marketing power as it pushes further into the healthcare sector.